Extended Data Fig. 2: Cost-effectiveness acceptability curve for spironolactone in addition to usual care versus usual care alone under complete case analysis with EQ-5D-5L weights for the quality-adjusted life years (QALY). | Nature Medicine

Extended Data Fig. 2: Cost-effectiveness acceptability curve for spironolactone in addition to usual care versus usual care alone under complete case analysis with EQ-5D-5L weights for the quality-adjusted life years (QALY).

From: Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial

Extended Data Fig. 2

The cost-effectiveness acceptability curve presents the probability of spironolactone in addition to usual care being cost-effective compared to usual care alone at different cost-effectiveness thresholds.

Back to article page